Trial reportFrontiers in neuroscience2026
Exploring the role of gut microbiota in potential mechanism of ketogenic diet in alleviating Parkinson's disease symptoms.
Trial report in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The ketogenic diet in Parkinson's disease: mechanisms, evidence, and clinical practice.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current clinical research suggests that the ketogenic diet (KD) intervention can alleviate Parkinson's disease (PD) symptoms. However, the underlying mechanisms remain unclear. This pilot study explored the potential link between KD-induced clinical improvements and gut microbiota alterations. Methods: We engaged 27 PD patients in a 12-week ketogenic dietary trial (16 completed) and employed 16S rRNA sequencing to analyze gut microbiota differences compared to 27 healthy controls. Results: Baseline analysis revealed distinct dysbiosis in PD patients, characterized by increased abundance of Enterobacteriaceae. Following the 12-week intervention, patients exhibited significant improvements in both motor (MDS-UPDRS Part III, Conclusion: These findings suggest that the therapeutic effects of the ketogenic diet in PD are associated with specific remodeling of the gut microbiota, particularly the enrichment of potential beneficial taxa and reduction of pro-inflammatory genera. Clinical trial registration: https://www.chictr.org.cn/index.html, Unique Identifier: ChiCTR2100045394.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.